Literature DB >> 18618306

Bioadhesive ranitidine hydrochloride for gastroretention with controlled microenvironmental pH.

Anuradha Adhikary1, Pradeep R Vavia.   

Abstract

Ranitidine hydrochloride is a H(2) receptor blocker used in the treatment of gastric ulcers. Pharmacological factors, in addition to the dosage regimen, favor development of a sustained-release system for ranitidine especially in the therapeutic condition of erosive esophagitis. This investigation delves into the development of bioadhesive type of gastroretentive formulation (tablets) of ranitidine. The effect of mucoadhesive polymers such as Carbopol, hydroxypropyl methyl cellulose, and dextrose were studied. Mucoadhesion, in vitro drug release profile, water uptake, and swelling of the tablet were evaluated. Alkalizing agents were incorporated in an attempt to maintain an alkaline microenvironment within the tablet and improve the stability of the drug in acidic medium. The stability was evaluated using dye test and degradation studies. The drug release profiles were fit into various kinetic models.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18618306     DOI: 10.1080/03639040801928812

Source DB:  PubMed          Journal:  Drug Dev Ind Pharm        ISSN: 0363-9045            Impact factor:   3.225


  3 in total

1.  Effect of bioadhesion on initial in vitro buoyancy of effervescent floating matrix tablets of ciprofloxacin HCL.

Authors:  Jeetendra Singh Negi; Abhinav Trivedi; Praveen Khanduri; Vandana Negi; Nikhil Kasliwal
Journal:  J Adv Pharm Technol Res       Date:  2011-04

2.  A novel in situ gel formulation of ranitidine for oral sustained delivery.

Authors:  Haoping Xu; Min Shi; Ying Liu; Jinling Jiang; Tao Ma
Journal:  Biomol Ther (Seoul)       Date:  2014-02       Impact factor: 4.634

3.  Design, development and optimization of sustained release floating, bioadhesive and swellable matrix tablet of ranitidine hydrochloride.

Authors:  Birhanu Nigusse; Tsige Gebre-Mariam; Anteneh Belete
Journal:  PLoS One       Date:  2021-06-25       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.